Abstract
To the Editor:— The suggestion made by Dr. Stock is based on solid scientific fact. I am not aware, however, of a malabsorption syndrome (like combined sclerosis) operating in patients with Parkinson's syndrome. This point would be a good subject matter for investigation. The actual therapeutic trial of 2-amino-4-hydroxy -6- 7 - dimethyltetrahydropteridine in selected individuals with Parkinson's syndrome might also be warrented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
